Slide 1: Commercial Momentum and Pipeline Progress
Commercial Momentum and Pipeline Progress June 2026 ASX:CBL \
Slide 2: About Us
About Us Control Bionics Limited (ASX: CBL) (“Control Bionics” or “the Company”), a global neurotechnology company commercialising non-invasive neural-signal technology, is pleased to provide stakeholders with an update on the significant progress the business has made in building customer relations
Slide 3: Assistive Technology
Assistive Technology
Slide 4: Assistive Technology
Assistive Technology Control Bionics’ Assistive Technology business continues to provide the commercial foundation for the Company, with the NeuroNode remaining a differentiated access technology for people with complex communication and physical needs. The Company continues to receive strong valida
Slide 5: Tobii Dynavox PRC-Saltillo
Assistive Technology Tobii Dynavox PRC-Saltillo Following the signing of Control Bionics’ Control Bionics signed a US-wide distribution initial US five-state agreement with Tobii agreement with PRC-Saltillo in January 2026. Dynavox, the CBL team has completed Funded sales have already commenced, and
Slide 6: New York Board of Education
Assistive Technology New York NextLeveliOS Tablets Germany Board of Education Control Bionics has entered into In April 2026, Control Bionics signed a The NeuroNode was awarded a long-term supply agreement Letter of Intent with a launch customer HMV insurance coverage in with the New York Board of f
Slide 7: NeuroTech Solutions
NeuroTech Solutions
Slide 8: NeuroTech Solutions
NeuroTech Solutions Control Bionics’ NeuroTech Solutions pillar is focused on applying the Company’s proprietary sEMG technology through NeuroStrip in sports performance, return-to-play assessment, athlete profiling, rehabilitation and clinical use cases. NeuroStrip is a lightweight, wearable sEMG p
Slide 9: Australia
Australia Control Bionics is currently engaged with numerous leading Australian sporting and rehabilitation organisations to assess the use of NeuroStrip in athlete rehabilitation, return-to-play decision making, player profiling and clinical rehabilitation – these include: Sport Teams Control Bioni
Slide 10: Australia
Australia Australian national Control Bionics is engaged with an Australian national governing body for a governing body for a major winter sport. The initial engagement Organisations major winter sport is structured as a three-month trial and is focused on return-to-play applications. Control Bioni
Slide 11: International
International Control Bionics’ technology has had interest from beyond our core markets of the US and Australia. The business is actively engaged with a number of international sports groups – these include: Sport Major International A Control Bionics team is currently in Europe working with a well-
Slide 12: United States
United States The United States remains a key market for Control Bionics’ NeuroTech Solutions business, with activity underway across both sport and rehabilitation. Sport Ohio University Weber State NeuroBounce Multiple projects are underway with Control Bionics is engaged with Control Bionics conti
Slide 13: United States
United States Bay State Control Bionics is rolling out NeuroStrip to the first clinic within Bay State Physical Therapy’s network. Bay State Physical Therapy represents a significant potential Physical Therapy rehabilitation channel, with a network of Rehabilitation more than 160 clinics across the
Slide 14: United States
United States Rehabilitation Mountain Land Physical Therapy Control Bionics continues to engage with Mountain Land Physical Therapy, a US rehabilitation and sports performance provider with approximately 70 clinics in the US. Mountain Land is active across rehabilitation and sports performance use c
Slide 15: Japan
Japan Rehabilitation Stroke Lab Control Bionics is working closely with Stroke Lab in Japan, a specialist neurological rehabilitation clinic dedicated to treating clients with complex neurological conditions. A patient recovering from a serious brain bleed had been left with significant walking diff
Slide 16: Platform and Medical Technologies
Platform and Medical Technologies
Slide 17: Platform and Medical Technologies
Platform and Medical Technologies Control Bionics’ Platform and Medical Technologies pillar is focused on commercialising the Company’s neural-signal platform beyond its current device applications. This includes technology partnerships, research collaborations, software integrations, data applicati
Slide 18: Apple BCI
Apple BCI Following Control Bionics’ agreement to commercialise Apple’s BCI protocol, the Company is currently building this capability into the next generation of its software for wide commercial release in Q3 2026. As previously announced, Apple BCI integration is expected to represent a significa
Slide 19: Technology and Research Partnerships
Technology and Research Partnerships Control Bionics has either engaged with, or is in discussions to partner with, a number of leading clinical, research and academic organisations for access to its platform. These include: • Mayo Clinic; • Barrow Neurological Institute; • Penn State Health; • Univ
Slide 20: Summary
Summary Control Bionics has made significant progress in recent months across each of its three strategic pillars. In Assistive Technology, the Company continues to benefit from the dedicated E2513 HCPCS code, increasing funding validation, US distribution partner activation, new iOS tablet opportun
Slide 21: Investor and Media Enquiries
Investor and Media Enquiries Jeremy Steele CEO & Managing Director Control Bionics Limited Email: jsteele@controlbionics.com Website: www.controlbionics.com
Slide 22: About Control Bionics
About Control Bionics Control Bionics is a global neurotechnology company that captures the body’s electrical signals generated by muscles and converts them into actionable data. The Company’s proprietary technology platform is deployed across assistive communication, sports performance, rehabilitat